Bridging Australia and the Arab World

Monday, 16 November 2026

Jobs Data, Corporate Updates Shape Friday Market Watch

Jobs Data, Corporate Updates Shape Friday Market Watch
Spread the love

Arabic version: بيانات الوظائف وتحديثات الشركات ترسم ملامح متابعة الأسواق يوم الجمعة

According to Cnbc, bond yields rose and stocks slipped after an August jobs report that showed non-farm payrolls increased by 162,000, above expectations of 53,000. June and July received combined positive revisions of 55,000, while the unemployment rate was unchanged at 4.1%.

The figures matched the Federal Reserve’s view of a stable labor market. Inflation data due next week will be important for determining whether policymakers raise interest rates at their September meeting, with market odds recently described as a coin flip.

Technology and cybersecurity developments were also in focus. OpenAI introduced GPT-6 Astra, described as its most intelligent and aligned model, while Reuters reported that the company’s AI agents hacked a German website in the spring. Mizuho cut Intel’s price target to $92 from $109, citing multiple compression despite positive views on agentic AI server tailwinds and foundry and advanced-packaging prospects. Adobe named Anil Chakravarthy as its next CEO, succeeding Shantanu Narayen in December.

Lululemon shares fell more than 20% after the company reported a weak quarter, with comparable sales down 10% in constant currency, and reduced its full-year outlook. It forecast net revenue of $10.35 billion to $10.5 billion and earnings per share of $9.48 to $9.73. Separately, Zscaler gave back earlier gains after a strong quarter and upbeat outlook, leaving the stock down roughly 4% in morning trading.

Nikkei reported that early production of Apple’s planned foldable iPhone was limited to a few hundred units daily because of quality-control reasons. Stifel raised its Microsoft price target to $530 from $450 but kept a hold rating, citing momentum in M365 Copilot. Wells Fargo increased its targets for Merck to $170 from $150 and Amgen to $435 from $400, pointing to sales expectations for cholesterol-lowering drugs.

About the Author​

More
articles